5-LIPOXYGENASE-ACTIVATING PROTEIN STIMULATES THE UTILIZATION OF ARACHIDONIC-ACID BY 5-LIPOXYGENASE

被引:176
作者
ABRAMOVITZ, M
WONG, E
COX, ME
RICHARDSON, CD
LI, C
VICKERS, PJ
机构
[1] MERCK FROSST CTR THERAPEUT RES,DEPT MOLEC BIOL,POB 1005,POINTE CLAIRE H9R 4P8,PQ,CANADA
[2] MERCK FROSST CTR THERAPEUT RES,DEPT PHARMACOL,POINTE CLAIRE H9R 4P8,PQ,CANADA
[3] BIOTECHNOL RES INST,VIROL GRP,MONTREAL,PQ,CANADA
[4] MERCK FROSST CTR THERAPEUT RES,DEPT MED CHEM,POINTE CLAIRE H9R 4P8,PQ,CANADA
来源
EUROPEAN JOURNAL OF BIOCHEMISTRY | 1993年 / 215卷 / 01期
关键词
D O I
10.1111/j.1432-1033.1993.tb18012.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
5-Lipoxygenase (5-LO) and its activating protein (FLAP) are both required for cellular leukotriene (LT) synthesis, with 5-LO catalyzing both the synthesis of (5S)-5-hydroperoxy-6,8,11,14-eicosatetraenoic acid (5-HPETE) from arachidonic acid and the subsequent synthesis of LTA4 from 5-HPETE. We have previously expressed both human 5-LO and human FLAP to high levels in Spodoptera frugiperda (Sf9) insect cells, using recombinant baculoviruses. To study the mechanism by which FLAP activates 5-LO, we compared cellular 5-LO activity in Sf9 cells expressing this enzyme to that in Sf9 cells coexpressing FLAP and 5-LO. In this system, FLAP stimulates the utilization of arachidonic acid by 5-LO as a substrate, and increases the efficiency with which 5-LO converts 5-HPETE to LTA4. LT synthesis in cells coexpressing FLAP and 5-LO is inhibited by 3-[l-(p-chlorophenyl)-5-isopropyl-3-tert-butylthio-1H-indol-2-yl]-2,2-dimethyl-propanoic acid (MK-886), an LT biosynthesis inhibitor which specifically binds to FLAP. These studies in Sf9 cells, together with our recent demonstration that FLAP specifically binds arachidonic acid, suggests that FLAP activates 5-LO by acting as an arachidonic acid transfer protein.
引用
收藏
页码:105 / 111
页数:7
相关论文
共 41 条
  • [1] PHARMACOLOGY OF MK-0591 (3-[1-(4-CHLOROBENZYL)-3-(T-BUTYLTHIO)-5-(QUINOLIN-2-YL-METHOXY)-INDOL-2-YL]-2,2-DIMETHYL PROPANOIC ACID), A POTENT, ORALLY ACTIVE LEUKOTRIENE BIOSYNTHESIS INHIBITOR
    BRIDEAU, C
    CHAN, C
    CHARLESON, S
    DENIS, D
    EVANS, JF
    FORDHUTCHINSON, AW
    FORTIN, R
    GILLARD, JW
    GUAY, J
    GUEVREMONT, D
    HUTCHINSON, JH
    JONES, TR
    LEGER, S
    MANCINI, JA
    MCFARLANE, CS
    PICKETT, C
    PIECHUTA, H
    PRASIT, P
    RIENDEAU, D
    ROUZER, CA
    TAGARI, P
    VICKERS, PJ
    YOUNG, RN
    ABRAHAM, WM
    [J]. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1992, 70 (06) : 799 - 807
  • [2] CHARLESON S, 1992, MOL PHARMACOL, V41, P873
  • [3] HUMAN-ENDOTHELIAL CELLS STIMULATE LEUKOTRIENE SYNTHESIS AND CONVERT GRANULOCYTE RELEASED LEUKOTRIENE-A4 INTO LEUKOTRIENE-B4, LEUKOTRIENE-C4, LEUKOTRIENE-D4 AND LEUKOTRIENE-E4
    CLAESSON, HE
    HAEGGSTROM, J
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1988, 173 (01): : 93 - 100
  • [4] A NOVEL ARACHIDONIC ACID-SELECTIVE CYTOSOLIC PLA2 CONTAINS A CA2+-DEPENDENT TRANSLOCATION DOMAIN WITH HOMOLOGY TO PKC AND GAP
    CLARK, JD
    LIN, LL
    KRIZ, RW
    RAMESHA, CS
    SULTZMAN, LA
    LIN, AY
    MILONA, N
    KNOPF, JL
    [J]. CELL, 1991, 65 (06) : 1043 - 1051
  • [5] DENIS D, 1991, J BIOL CHEM, V266, P5072
  • [6] REQUIREMENT OF A 5-LIPOXYGENASE-ACTIVATING PROTEIN FOR LEUKOTRIENE SYNTHESIS
    DIXON, RAF
    DIEHL, RE
    OPAS, E
    RANDS, E
    VICKERS, PJ
    EVANS, JF
    GILLARD, JW
    MILLER, DK
    [J]. NATURE, 1990, 343 (6255) : 282 - 284
  • [7] EVANS JF, 1991, MOL PHARMACOL, V40, P22
  • [8] FORDHUTCHINSON AW, 1989, LEUKOTRIENES LIPOXYG, V2, P405
  • [9] FORDHUTCHINSON AW, 1985, LEUKOTRIENES THEIR B, P141
  • [10] NATIVE AND MUTANT 5-LIPOXYGENASE EXPRESSION IN A BACULOVIRUS INSECT CELL SYSTEM
    FUNK, CD
    GUNNE, H
    STEINER, H
    IZUMI, T
    SAMUELSSON, B
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (08) : 2592 - 2596